Clinical Trials on Recurrent Myelodysplastic/Myeloproliferative Neoplasm

Total 7800 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Recurrent Myeloproliferative Neoplasm

United States
M.D. Anderson Cancer Center

Active, not recruiting

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic/Myeloproliferative Neoplasm | Refractory Myelodysplastic/Myeloproliferative Neoplasm

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Myeloproliferative Neoplasm

United States
M.D. Anderson Cancer Center

Recruiting

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Bellicum Pharmaceuticals

Withdrawn

Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Hodgkin Lymphoma | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Recurrent Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Childhood Acute Myeloid Leukemia and other conditions

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia Post Cytotoxic Therapy | Acute Myeloid Leukemia, Myelodysplasia-Related
BeiGene

Recruiting

A Study of BGB-11417 in Participants With Myeloid Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelodysplastic/Myeloproliferative Neoplasm

China, United States, Australia, Spain, Korea, Republic of, New Zealand, Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

Anemia | Myelofibrosis | Myelodysplastic/Myeloproliferative Neoplasm

United States
Karolinska University Hospital
Nordic MDS Group

Recruiting

A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS

Myelodysplastic Syndromes | Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts | Mixed Myelodysplastic/Myeloproliferative Disease

Sweden
The First Affiliated Hospital of Soochow University

Enrolling by invitation

Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults

Myelodysplastic/Myeloproliferative Neoplasms | Adult

China
M.D. Anderson Cancer Center

Not yet recruiting

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Myeloproliferative Neoplasm | Myelodysplastic Neoplasm | Pathway Mutant Myelodysplastic Syndromes

United States
European Working Group of MDS in Childhood

Unknown

Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome

Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

Germany
University of Rochester

Not yet recruiting

A Telehealth Advance Care Planning Intervention (TeleSICP)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Myeloid Malignancy | Myelodysplastic/Myeloproliferative Neoplasm

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Cholecalciferol in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic Syndrome With Isolated Del(5q)

United States
CTI BioPharma
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
National Cancer Institute (NCI)

Completed

Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia

Myelodysplastic Syndromes | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Myelodysplastic/Myeloproliferative Neoplasms

United States
Fred Hutchinson Cancer Center
ImmunoGen, Inc.

Recruiting

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Mixed Phenotype Acute Leukemia

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes

Myelodysplastic Syndromes | Myelodysplastic/Myeloproliferative Neoplasms

United States, Canada, Australia, Puerto Rico
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Stanford University
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm

United States
University Health Network, Toronto

Completed

Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm (DSC-SR)

Myelodysplastic/Myeloproliferative Neoplasm | Allogeneic Hematopoietic Cell Transplant | Steroid Refractory GVHD

Canada
Fallon Clinic

Completed

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Anemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
University of Washington

Completed

Interleukin-2 in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Recurrent Adult Acute Myeloid Leukemia

United States
Children's Oncology Group

Not yet recruiting

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Juvenile Myelomonocytic Leukemia
Astex Pharmaceuticals, Inc.

Terminated

A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

Acute Myeloid Leukemia | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm

United States, Canada
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia,...

United States
Vion Pharmaceuticals

Completed

VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
European Organisation for Research and Treatment...

Unknown

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

Belgium, Netherlands, Germany, Italy, United Kingdom, Austria, Czech Republic, Croatia, Turkey, Switzerland
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Blasts More Than 20 Percent of Bone Marrow Nucleated Cells | Blasts More Than 20 Percent of Peripheral Blood White Cells

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome

United States
Vion Pharmaceuticals

Completed

3-AP and Cytarabine in Treating Patients With Hematologic Cancer

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Medical Research Council

Completed

Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United Kingdom
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | Refractory Anemia With Excess... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Novartis

Recruiting

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome

United States
Asan Medical Center

Completed

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

Korea, Republic of
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Neoplasms

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States

Clinical Trials on Recurrent Myelodysplastic/Myeloproliferative Neoplasm

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations